NextCure stock draws additional buying from ADAR1 funds

ADAR1 Capital Management reported purchases of NextCure common stock in three transactions on October 23, October 26 and October 27, 2026. The SEC Form 4 filing, reviewed by StockTitan, identifies ADAR1 Capital Management and Daniel Schneeberger as reporting persons linked to the holdings.

Three purchases in late October

The filing states that private investment funds managed by ADAR1 Capital Management acquired 5,626 shares on October 23, 1,672 shares on October 26 and 3,553 shares on October 27. The reported weighted average purchase prices were 4.8294 US dollars, 5.0344 US dollars and 5.0953 US dollars per share, respectively.

The filing identifies both ADAR1 Capital Management and Schneeberger as a director and 10% owner of NextCure. The securities are held indirectly through private investment funds, while the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.

What the filing means for investors

The transactions show additional buying by a shareholder group connected with the company, but an insider purchase does not by itself establish a change in NextCure's operating outlook or guarantee a stock-market gain. Investors will continue to weigh the company's clinical progress, financing needs and strategic plans alongside ownership disclosures.

NextCure's clinical focus

NextCure is a United States clinical-stage biopharmaceutical company developing immunomedicines for cancer and other immune-related diseases. According to its corporate profile, the company uses its Functional, Integrated, NextCure Discovery in Immuno-Oncology platform to study immune cells and identify targets for new treatments. Its development focus includes patients who do not respond to current therapies and cancer types that remain inadequately addressed.

US equities trade in the broader S&P 500 market context.

More news and analyses on NextCure stock